{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:19Z","timestamp":1792852519368,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00259-023-06338-6","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T05:01:46Z","timestamp":1689397306000},"page":"2935-2939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?"],"prefix":"10.1007","volume":"50","author":[{"given":"Rubel","family":"Chakravarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"6338_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"6338_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12:1557\u201369. https:\/\/doi.org\/10.7150\/thno.69475.","journal-title":"Theranostics"},{"key":"6338_CR4","doi-asserted-by":"publisher","first-page":"3948873","DOI":"10.1155\/2022\/3948873","volume":"2022","author":"H Roustaei","year":"2022","unstructured":"Roustaei H, Kiamanesh Z, Askari E, Sadeghi R, Aryana K, Treglia G. Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents? Contrast Media Mol Imaging. 2022;2022:3948873. https:\/\/doi.org\/10.1155\/2022\/3948873.","journal-title":"Contrast Media Mol Imaging"},{"key":"6338_CR5","first-page":"4767","volume":"62","author":"JD Cheng","year":"2002","unstructured":"Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002;62:4767\u201372.","journal-title":"Cancer Res"},{"key":"6338_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000069863","volume":"26","author":"RD Hofheinz","year":"2003","unstructured":"Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, J\u00e4ger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26:44\u20138. https:\/\/doi.org\/10.1159\/000069863.","journal-title":"Onkologie."},{"key":"6338_CR7","doi-asserted-by":"publisher","first-page":"854658","DOI":"10.3389\/fonc.2022.854658","volume":"12","author":"R Huang","year":"2022","unstructured":"Huang R, Pu Y, Huang S, Yang C, Yang F, Pu Y, et al. FAPI-PET\/CT in cancer imaging: a potential novel molecule of the century. Front Oncol. 2022;12:854658. https:\/\/doi.org\/10.3389\/fonc.2022.854658.","journal-title":"Front Oncol"},{"key":"6338_CR8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265594","author":"M Ora","year":"2023","unstructured":"Ora M, Soni N, Nazar AH, Dixit M, Singh R, Puri S, et al. Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.123.265594.","journal-title":"J Nucl Med"},{"key":"6338_CR9","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","volume":"49","author":"M Li","year":"2022","unstructured":"Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49:2844\u201368. https:\/\/doi.org\/10.1007\/s00259-022-05706-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR10","first-page":"476","volume":"11","author":"ES Moon","year":"2021","unstructured":"Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021;11:476\u201391.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"6338_CR11","first-page":"537","volume":"11","author":"C Qin","year":"2021","unstructured":"Qin C, Song Y, Cai W, Lan X. Dimeric FAPI with potential for tumor theranostics. Am J Nucl Med Mol Imaging. 2021;11:537\u201341.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"6338_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","volume":"63","author":"M Xu","year":"2022","unstructured":"Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J Nucl Med. 2022;63:952\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262533.","journal-title":"J Nucl Med"},{"key":"6338_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00259-022-05766-0","volume":"49","author":"MH Younis","year":"2022","unstructured":"Younis MH, Malih S, Lan X, Rasaee MJ, Cai W. Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond. Eur J Nucl Med Mol Imaging. 2022;49:1773\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05766-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR14","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367. https:\/\/doi.org\/10.1007\/s00259-022-05842-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06272-7","author":"J Millul","year":"2023","unstructured":"Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06272-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","volume":"58","author":"GP Nicolas","year":"2017","unstructured":"Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the mass effect. J Nucl Med. 2017;58:1435\u201341. https:\/\/doi.org\/10.2967\/jnumed.117.191684.","journal-title":"J Nucl Med"},{"key":"6338_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00259-006-0180-9","volume":"34","author":"I Dijkgraaf","year":"2007","unstructured":"Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Oyen WJ, Corstens FH, et al. Improved targeting of the \u03b1v\u03b23 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267\u201373. https:\/\/doi.org\/10.1007\/s00259-006-0180-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6338_CR18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265599","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.123.265599.","journal-title":"J Nucl Med"},{"key":"6338_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/mp060049x","volume":"3","author":"S Liu","year":"2006","unstructured":"Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin \u03b1v\u03b23 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472\u201387. https:\/\/doi.org\/10.1021\/mp060049x.","journal-title":"Mol Pharm"},{"key":"6338_CR20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265383","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wen X, Xu W, Pang Y, Sun L, Wu X, et al. Clinical evaluation of 68Ga-FAPI-RGD for imaging of fibroblast activation protein and integrin \u03b1v\u03b23 in various cancer types. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.122.265383.","journal-title":"J Nucl Med"},{"key":"6338_CR21","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.7150\/thno.86007","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Jakobsson V, Wang J, Zhao T, Peng X, Li B, et al. Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023;13:2979\u201392. https:\/\/doi.org\/10.7150\/thno.86007.","journal-title":"Theranostics"},{"key":"6338_CR22","doi-asserted-by":"publisher","first-page":"115279","DOI":"10.1016\/j.ejmech.2023.115279","volume":"251","author":"Q Yan","year":"2023","unstructured":"Yan Q, Zhong J, Liu Y, Peng S, Feng P, Zhong Y, et al. Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-\u03b1v\u03b23. Eur J Med Chem. 2023;251:115279. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115279.","journal-title":"Eur J Med Chem."},{"key":"6338_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"6338_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"Y Liu","year":"2022","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49:871\u201380. https:\/\/doi.org\/10.1007\/s00259-021-05554-2.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06338-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T02:08:47Z","timestamp":1690596527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06338-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6338"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06338-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"15 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Weibo Cai declares conflict of interest with the following corporations: Actithera, Inc., Rad Source Technologies, Inc., Portrai, Inc., rTR Technovation Corporation, and Four Health Global Pharmaceuticals, Inc. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Studies with human participants or animals"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}